Q4 2025 Liquidia Corp Earnings Call Transcript
Key Points
- Liquidia Corp (LQDA) achieved rapid profitability within 120 days of launching YUTREPIA.
- YUTREPIA has been recognized as one of the top specialty drug launches over the past five years.
- The company has received over 3,600 unique patient referrals and shipped therapy for more than 2,900 patients since launch.
- Liquidia Corp (LQDA) reported a 74% growth in net product sales in Q4 2025 compared to Q3 2025.
- The company ended 2025 with $190.7 million in cash and cash equivalents, generating $33 million of positive cash flow in Q4 alone.
- The market share for YUTREPIA is difficult to determine due to competitors not disclosing their numbers.
- There is potential competition from new oral prostacyclin receptor agonists entering the market.
- The company faces ongoing legal uncertainties, with no new updates on the legal front.
- The inhaled treprostinil market is highly competitive, with existing products like UPTRAVI maintaining stable NRx numbers.
- There is a need for continued expansion into additional disease areas to sustain growth.
Good morning and welcome to the Liquidia Corporation full year 2025, financial results and corporate update conference call. My name is Josh and I will be your operator today. (Operator Instructions). Please note that today's call is being recorded. I'll now turn the call over to Jason Adair, Chief Business Officer.
Thank you, and good morning, everyone. It's my pleasure to welcome you to our full year 2025 financial results and corporate update call. Joining me today are Dr. Roger Jeffs, Chief Executive Officer; Michael Kaseta, Chief Operating Officer and Chief Financial Officer; Dr. Rajeev Saggar, Chief Medical Officer; Scott Moomaw, Chief Commercial Officer; and Rusty Shundler, our General Counsel.
Before we begin, please note that today's discussion will include forward-looking statements, including statements regarding future results, product performance and ongoing clinical or commercial activities. These statements are subject to risks and uncertainties that may cause actual results to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
